<DOC>
	<DOC>NCT02640443</DOC>
	<brief_summary>The investigators will evaluate whether sulfamethoxazole, a sulfamide antibiotic, improves the symptoms of primary PREPL deficiency (hypotonia-cystinuria syndrome and isolated PREPL deficiency).</brief_summary>
	<brief_title>Sulfamethoxazole for the Treatment of Primary PREPL Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Cystinuria</mesh_term>
	<mesh_term>Chromosome Deletion</mesh_term>
	<mesh_term>Intellectual Disability</mesh_term>
	<mesh_term>Muscle Hypotonia</mesh_term>
	<mesh_term>Craniofacial Abnormalities</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<criteria>patients with molecular confirmation of primary PREPL deficiency who are able to follow the study protocol (for the primary endpoint) who have given written informed consent age&lt;2m women of childbearing age unless using a reliable method for contraception and not pregnant at study entrance additional diagnosis with influence on muscle force not able to follow the study protocol (for the primary endpoint) history of sulfonamide hypersensitivity diminished renal function based on serum creatinine transaminases higher than 3 times the upper limit of normal for the pupillometry: eye pathology with the exception of refractive errors, drugs with influence on the pupillary light reflex</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>